nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A7—Temsirolimus—kidney cancer	0.0561	0.0939	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Temsirolimus—kidney cancer	0.0561	0.0939	CbGbCtD
Ziprasidone—CYP3A5—Temsirolimus—kidney cancer	0.0421	0.0705	CbGbCtD
Ziprasidone—KCNH2—Sunitinib—kidney cancer	0.0271	0.0454	CbGbCtD
Ziprasidone—HTR2C—Sorafenib—kidney cancer	0.0262	0.0439	CbGbCtD
Ziprasidone—CYP2D6—Temsirolimus—kidney cancer	0.0258	0.0432	CbGbCtD
Ziprasidone—CYP3A4—Everolimus—kidney cancer	0.0243	0.0407	CbGbCtD
Ziprasidone—CYP3A7—Paclitaxel—kidney cancer	0.0192	0.0322	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Paclitaxel—kidney cancer	0.0192	0.0322	CbGbCtD
Ziprasidone—CYP3A7—Sorafenib—kidney cancer	0.0171	0.0286	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Sorafenib—kidney cancer	0.0171	0.0286	CbGbCtD
Ziprasidone—CYP3A7—Vincristine—kidney cancer	0.0166	0.0278	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Vincristine—kidney cancer	0.0166	0.0278	CbGbCtD
Ziprasidone—CYP1A2—Pazopanib—kidney cancer	0.0164	0.0275	CbGbCtD
Ziprasidone—CYP3A4—Temsirolimus—kidney cancer	0.0164	0.0275	CbGbCtD
Ziprasidone—CYP3A5—Erlotinib—kidney cancer	0.0158	0.0264	CbGbCtD
Ziprasidone—CYP3A5—Paclitaxel—kidney cancer	0.0144	0.0242	CbGbCtD
Ziprasidone—CYP3A7—Sunitinib—kidney cancer	0.0138	0.0232	CbGbCtD
Ziprasidone—CYP3A7-CYP3A51P—Sunitinib—kidney cancer	0.0138	0.0232	CbGbCtD
Ziprasidone—CYP2D6—Pazopanib—kidney cancer	0.0135	0.0227	CbGbCtD
Ziprasidone—CYP3A5—Sorafenib—kidney cancer	0.0128	0.0215	CbGbCtD
Ziprasidone—CYP3A5—Vincristine—kidney cancer	0.0124	0.0208	CbGbCtD
Ziprasidone—CYP1A2—Erlotinib—kidney cancer	0.0117	0.0197	CbGbCtD
Ziprasidone—CYP3A5—Sunitinib—kidney cancer	0.0104	0.0174	CbGbCtD
Ziprasidone—CYP2D6—Erlotinib—kidney cancer	0.00967	0.0162	CbGbCtD
Ziprasidone—CYP1A2—Sorafenib—kidney cancer	0.00954	0.016	CbGbCtD
Ziprasidone—CYP3A4—Pazopanib—kidney cancer	0.00862	0.0144	CbGbCtD
Ziprasidone—CHRM3—ureter—kidney cancer	0.00816	0.204	CbGeAlD
Ziprasidone—CYP2D6—Sorafenib—kidney cancer	0.00786	0.0132	CbGbCtD
Ziprasidone—CYP2D6—Vinblastine—kidney cancer	0.00776	0.013	CbGbCtD
Ziprasidone—CYP3A4—Erlotinib—kidney cancer	0.00615	0.0103	CbGbCtD
Ziprasidone—CYP3A4—Paclitaxel—kidney cancer	0.00563	0.00943	CbGbCtD
Ziprasidone—CYP3A4—Sorafenib—kidney cancer	0.005	0.00837	CbGbCtD
Ziprasidone—CYP3A4—Vinblastine—kidney cancer	0.00494	0.00827	CbGbCtD
Ziprasidone—CYP3A4—Vincristine—kidney cancer	0.00485	0.00813	CbGbCtD
Ziprasidone—CYP2D6—Doxorubicin—kidney cancer	0.00477	0.00799	CbGbCtD
Ziprasidone—CYP3A4—Sunitinib—kidney cancer	0.00405	0.00678	CbGbCtD
Ziprasidone—CYP3A4—Doxorubicin—kidney cancer	0.00303	0.00508	CbGbCtD
Ziprasidone—CYP1A2—urine—kidney cancer	0.00201	0.0504	CbGeAlD
Ziprasidone—HTR2A—urine—kidney cancer	0.00157	0.0394	CbGeAlD
Ziprasidone—CYP3A4—urine—kidney cancer	0.00146	0.0365	CbGeAlD
Ziprasidone—CYP2D6—urine—kidney cancer	0.00143	0.0359	CbGeAlD
Ziprasidone—CYP3A7-CYP3A51P—nephron tubule—kidney cancer	0.00126	0.0316	CbGeAlD
Ziprasidone—H1F0—nephron tubule—kidney cancer	0.0011	0.0276	CbGeAlD
Ziprasidone—CYP3A7-CYP3A51P—cortex of kidney—kidney cancer	0.00108	0.0271	CbGeAlD
Ziprasidone—ADRA1B—renal system—kidney cancer	0.00106	0.0266	CbGeAlD
Ziprasidone—ADRA1B—kidney—kidney cancer	0.00103	0.0257	CbGeAlD
Ziprasidone—H1F0—renal system—kidney cancer	0.001	0.0251	CbGeAlD
Ziprasidone—H1F0—kidney—kidney cancer	0.000968	0.0242	CbGeAlD
Ziprasidone—H1F0—cortex of kidney—kidney cancer	0.000942	0.0236	CbGeAlD
Ziprasidone—H1F0—gonad—kidney cancer	0.000898	0.0225	CbGeAlD
Ziprasidone—H1F0—cardiac atrium—kidney cancer	0.000896	0.0225	CbGeAlD
Ziprasidone—HTR1D—kidney—kidney cancer	0.00075	0.0188	CbGeAlD
Ziprasidone—CHRM3—renal system—kidney cancer	0.000649	0.0163	CbGeAlD
Ziprasidone—HTR1A—renal system—kidney cancer	0.000646	0.0162	CbGeAlD
Ziprasidone—CHRM3—kidney—kidney cancer	0.000627	0.0157	CbGeAlD
Ziprasidone—ADRA2C—nephron tubule—kidney cancer	0.000625	0.0156	CbGeAlD
Ziprasidone—HTR7—renal system—kidney cancer	0.000618	0.0155	CbGeAlD
Ziprasidone—HTR7—kidney—kidney cancer	0.000597	0.015	CbGeAlD
Ziprasidone—ADRA1A—renal system—kidney cancer	0.000596	0.0149	CbGeAlD
Ziprasidone—KCNH2—renal system—kidney cancer	0.000575	0.0144	CbGeAlD
Ziprasidone—ADRA2C—renal system—kidney cancer	0.000568	0.0142	CbGeAlD
Ziprasidone—HTR7—gonad—kidney cancer	0.000554	0.0139	CbGeAlD
Ziprasidone—ADRA2C—kidney—kidney cancer	0.000549	0.0137	CbGeAlD
Ziprasidone—ADRA2C—cortex of kidney—kidney cancer	0.000535	0.0134	CbGeAlD
Ziprasidone—CYP3A5—nephron tubule—kidney cancer	0.000523	0.0131	CbGeAlD
Ziprasidone—KCNH2—cardiac atrium—kidney cancer	0.000515	0.0129	CbGeAlD
Ziprasidone—ADRA2C—cardiac atrium—kidney cancer	0.000508	0.0127	CbGeAlD
Ziprasidone—CYP1A2—renal system—kidney cancer	0.000493	0.0123	CbGeAlD
Ziprasidone—CYP3A5—renal system—kidney cancer	0.000475	0.0119	CbGeAlD
Ziprasidone—CYP3A5—kidney—kidney cancer	0.000459	0.0115	CbGeAlD
Ziprasidone—CYP3A5—cortex of kidney—kidney cancer	0.000447	0.0112	CbGeAlD
Ziprasidone—ADRA2A—cortex of kidney—kidney cancer	0.000427	0.0107	CbGeAlD
Ziprasidone—ADRA2A—gonad—kidney cancer	0.000406	0.0102	CbGeAlD
Ziprasidone—ADRA2A—cardiac atrium—kidney cancer	0.000406	0.0102	CbGeAlD
Ziprasidone—HTR2A—renal system—kidney cancer	0.000385	0.00965	CbGeAlD
Ziprasidone—HTR2A—kidney—kidney cancer	0.000372	0.00933	CbGeAlD
Ziprasidone—CYP3A4—renal system—kidney cancer	0.000357	0.00893	CbGeAlD
Ziprasidone—CYP2D6—renal system—kidney cancer	0.000351	0.00879	CbGeAlD
Ziprasidone—HTR2A—gonad—kidney cancer	0.000345	0.00865	CbGeAlD
Ziprasidone—CYP3A4—kidney—kidney cancer	0.000345	0.00864	CbGeAlD
Ziprasidone—CYP2D6—kidney—kidney cancer	0.000339	0.0085	CbGeAlD
Ziprasidone—Myalgia—Paclitaxel—kidney cancer	8.58e-05	0.000296	CcSEcCtD
Ziprasidone—Chest pain—Paclitaxel—kidney cancer	8.58e-05	0.000296	CcSEcCtD
Ziprasidone—Mediastinal disorder—Capecitabine—kidney cancer	8.57e-05	0.000295	CcSEcCtD
Ziprasidone—Anxiety—Paclitaxel—kidney cancer	8.55e-05	0.000295	CcSEcCtD
Ziprasidone—Face oedema—Doxorubicin—kidney cancer	8.55e-05	0.000295	CcSEcCtD
Ziprasidone—Decreased appetite—Gemcitabine—kidney cancer	8.54e-05	0.000295	CcSEcCtD
Ziprasidone—Hypersensitivity—Dactinomycin—kidney cancer	8.54e-05	0.000295	CcSEcCtD
Ziprasidone—Chills—Capecitabine—kidney cancer	8.53e-05	0.000294	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	8.52e-05	0.000294	CcSEcCtD
Ziprasidone—Arrhythmia—Capecitabine—kidney cancer	8.49e-05	0.000293	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Gemcitabine—kidney cancer	8.48e-05	0.000293	CcSEcCtD
Ziprasidone—Fatigue—Gemcitabine—kidney cancer	8.47e-05	0.000292	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Vincristine—kidney cancer	8.47e-05	0.000292	CcSEcCtD
Ziprasidone—Dizziness—Sorafenib—kidney cancer	8.42e-05	0.00029	CcSEcCtD
Ziprasidone—Constipation—Gemcitabine—kidney cancer	8.4e-05	0.00029	CcSEcCtD
Ziprasidone—Nausea—Erlotinib—kidney cancer	8.4e-05	0.00029	CcSEcCtD
Ziprasidone—Alopecia—Capecitabine—kidney cancer	8.4e-05	0.00029	CcSEcCtD
Ziprasidone—Dry mouth—Paclitaxel—kidney cancer	8.39e-05	0.00029	CcSEcCtD
Ziprasidone—Diarrhoea—Sunitinib—kidney cancer	8.38e-05	0.000289	CcSEcCtD
Ziprasidone—Ataxia—Doxorubicin—kidney cancer	8.33e-05	0.000287	CcSEcCtD
Ziprasidone—Mental disorder—Capecitabine—kidney cancer	8.33e-05	0.000287	CcSEcCtD
Ziprasidone—Asthenia—Dactinomycin—kidney cancer	8.32e-05	0.000287	CcSEcCtD
Ziprasidone—Confusional state—Paclitaxel—kidney cancer	8.3e-05	0.000286	CcSEcCtD
Ziprasidone—Blood creatinine increased—Doxorubicin—kidney cancer	8.3e-05	0.000286	CcSEcCtD
Ziprasidone—Erythema—Capecitabine—kidney cancer	8.27e-05	0.000285	CcSEcCtD
Ziprasidone—Malnutrition—Capecitabine—kidney cancer	8.27e-05	0.000285	CcSEcCtD
Ziprasidone—Dehydration—Doxorubicin—kidney cancer	8.24e-05	0.000284	CcSEcCtD
Ziprasidone—Body temperature increased—Vincristine—kidney cancer	8.19e-05	0.000282	CcSEcCtD
Ziprasidone—Abdominal pain—Vincristine—kidney cancer	8.19e-05	0.000282	CcSEcCtD
Ziprasidone—Liver function test abnormal—Doxorubicin—kidney cancer	8.18e-05	0.000282	CcSEcCtD
Ziprasidone—Infection—Paclitaxel—kidney cancer	8.17e-05	0.000282	CcSEcCtD
Ziprasidone—Flatulence—Capecitabine—kidney cancer	8.15e-05	0.000281	CcSEcCtD
Ziprasidone—Dizziness—Sunitinib—kidney cancer	8.1e-05	0.000279	CcSEcCtD
Ziprasidone—Feeling abnormal—Gemcitabine—kidney cancer	8.1e-05	0.000279	CcSEcCtD
Ziprasidone—Shock—Paclitaxel—kidney cancer	8.09e-05	0.000279	CcSEcCtD
Ziprasidone—Vomiting—Sorafenib—kidney cancer	8.09e-05	0.000279	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Doxorubicin—kidney cancer	8.09e-05	0.000279	CcSEcCtD
Ziprasidone—Nervous system disorder—Paclitaxel—kidney cancer	8.07e-05	0.000278	CcSEcCtD
Ziprasidone—Hypokalaemia—Doxorubicin—kidney cancer	8.06e-05	0.000278	CcSEcCtD
Ziprasidone—Thrombocytopenia—Paclitaxel—kidney cancer	8.06e-05	0.000278	CcSEcCtD
Ziprasidone—Tachycardia—Paclitaxel—kidney cancer	8.03e-05	0.000277	CcSEcCtD
Ziprasidone—Rash—Sorafenib—kidney cancer	8.03e-05	0.000277	CcSEcCtD
Ziprasidone—Dermatitis—Sorafenib—kidney cancer	8.02e-05	0.000277	CcSEcCtD
Ziprasidone—Back pain—Capecitabine—kidney cancer	8e-05	0.000276	CcSEcCtD
Ziprasidone—Breast disorder—Doxorubicin—kidney cancer	8e-05	0.000276	CcSEcCtD
Ziprasidone—Skin disorder—Paclitaxel—kidney cancer	7.99e-05	0.000276	CcSEcCtD
Ziprasidone—Headache—Sorafenib—kidney cancer	7.97e-05	0.000275	CcSEcCtD
Ziprasidone—Muscle spasms—Capecitabine—kidney cancer	7.95e-05	0.000274	CcSEcCtD
Ziprasidone—Hyperhidrosis—Paclitaxel—kidney cancer	7.95e-05	0.000274	CcSEcCtD
Ziprasidone—Diarrhoea—Dactinomycin—kidney cancer	7.93e-05	0.000274	CcSEcCtD
Ziprasidone—Nasopharyngitis—Doxorubicin—kidney cancer	7.92e-05	0.000273	CcSEcCtD
Ziprasidone—Anorexia—Paclitaxel—kidney cancer	7.84e-05	0.000271	CcSEcCtD
Ziprasidone—Gastritis—Doxorubicin—kidney cancer	7.84e-05	0.00027	CcSEcCtD
Ziprasidone—Clozapine—CYP1A1—kidney cancer	7.82e-05	0.285	CrCbGaD
Ziprasidone—Vision blurred—Capecitabine—kidney cancer	7.8e-05	0.000269	CcSEcCtD
Ziprasidone—Vomiting—Sunitinib—kidney cancer	7.79e-05	0.000269	CcSEcCtD
Ziprasidone—Body temperature increased—Gemcitabine—kidney cancer	7.77e-05	0.000268	CcSEcCtD
Ziprasidone—Tremor—Capecitabine—kidney cancer	7.75e-05	0.000267	CcSEcCtD
Ziprasidone—Aripiprazole—ABCB1—kidney cancer	7.73e-05	0.282	CrCbGaD
Ziprasidone—Rash—Sunitinib—kidney cancer	7.72e-05	0.000266	CcSEcCtD
Ziprasidone—Dermatitis—Sunitinib—kidney cancer	7.71e-05	0.000266	CcSEcCtD
Ziprasidone—Trazodone—ABCB1—kidney cancer	7.69e-05	0.281	CrCbGaD
Ziprasidone—Hypotension—Paclitaxel—kidney cancer	7.69e-05	0.000265	CcSEcCtD
Ziprasidone—Headache—Sunitinib—kidney cancer	7.67e-05	0.000265	CcSEcCtD
Ziprasidone—Influenza—Doxorubicin—kidney cancer	7.65e-05	0.000264	CcSEcCtD
Ziprasidone—Dysphagia—Doxorubicin—kidney cancer	7.65e-05	0.000264	CcSEcCtD
Ziprasidone—Anaemia—Capecitabine—kidney cancer	7.65e-05	0.000264	CcSEcCtD
Ziprasidone—Hypersensitivity—Vincristine—kidney cancer	7.63e-05	0.000263	CcSEcCtD
Ziprasidone—Eosinophilia—Doxorubicin—kidney cancer	7.58e-05	0.000261	CcSEcCtD
Ziprasidone—Nausea—Sorafenib—kidney cancer	7.56e-05	0.000261	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Paclitaxel—kidney cancer	7.5e-05	0.000259	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—kidney cancer	7.46e-05	0.000257	CcSEcCtD
Ziprasidone—Insomnia—Paclitaxel—kidney cancer	7.44e-05	0.000257	CcSEcCtD
Ziprasidone—Vertigo—Capecitabine—kidney cancer	7.43e-05	0.000256	CcSEcCtD
Ziprasidone—Asthenia—Vincristine—kidney cancer	7.43e-05	0.000256	CcSEcCtD
Ziprasidone—Syncope—Capecitabine—kidney cancer	7.42e-05	0.000256	CcSEcCtD
Ziprasidone—Leukopenia—Capecitabine—kidney cancer	7.41e-05	0.000255	CcSEcCtD
Ziprasidone—Paraesthesia—Paclitaxel—kidney cancer	7.39e-05	0.000255	CcSEcCtD
Ziprasidone—Vomiting—Dactinomycin—kidney cancer	7.37e-05	0.000254	CcSEcCtD
Ziprasidone—Dyspnoea—Paclitaxel—kidney cancer	7.34e-05	0.000253	CcSEcCtD
Ziprasidone—Somnolence—Paclitaxel—kidney cancer	7.31e-05	0.000252	CcSEcCtD
Ziprasidone—Palpitations—Capecitabine—kidney cancer	7.31e-05	0.000252	CcSEcCtD
Ziprasidone—Rash—Dactinomycin—kidney cancer	7.31e-05	0.000252	CcSEcCtD
Ziprasidone—Nausea—Sunitinib—kidney cancer	7.27e-05	0.000251	CcSEcCtD
Ziprasidone—Loss of consciousness—Capecitabine—kidney cancer	7.27e-05	0.000251	CcSEcCtD
Ziprasidone—Dyspepsia—Paclitaxel—kidney cancer	7.24e-05	0.00025	CcSEcCtD
Ziprasidone—Cough—Capecitabine—kidney cancer	7.22e-05	0.000249	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—kidney cancer	7.16e-05	0.000247	CcSEcCtD
Ziprasidone—Decreased appetite—Paclitaxel—kidney cancer	7.15e-05	0.000247	CcSEcCtD
Ziprasidone—Hypertension—Capecitabine—kidney cancer	7.14e-05	0.000246	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—kidney cancer	7.11e-05	0.000245	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Paclitaxel—kidney cancer	7.1e-05	0.000245	CcSEcCtD
Ziprasidone—Fatigue—Paclitaxel—kidney cancer	7.09e-05	0.000245	CcSEcCtD
Ziprasidone—Diarrhoea—Vincristine—kidney cancer	7.09e-05	0.000244	CcSEcCtD
Ziprasidone—Asthenia—Gemcitabine—kidney cancer	7.05e-05	0.000243	CcSEcCtD
Ziprasidone—Myalgia—Capecitabine—kidney cancer	7.04e-05	0.000243	CcSEcCtD
Ziprasidone—Chest pain—Capecitabine—kidney cancer	7.04e-05	0.000243	CcSEcCtD
Ziprasidone—Arthralgia—Capecitabine—kidney cancer	7.04e-05	0.000243	CcSEcCtD
Ziprasidone—Constipation—Paclitaxel—kidney cancer	7.04e-05	0.000243	CcSEcCtD
Ziprasidone—Anxiety—Capecitabine—kidney cancer	7.02e-05	0.000242	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	6.99e-05	0.000241	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—kidney cancer	6.99e-05	0.000241	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—kidney cancer	6.97e-05	0.00024	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—kidney cancer	6.92e-05	0.000239	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—kidney cancer	6.9e-05	0.000238	CcSEcCtD
Ziprasidone—Dry mouth—Capecitabine—kidney cancer	6.89e-05	0.000238	CcSEcCtD
Ziprasidone—Nausea—Dactinomycin—kidney cancer	6.89e-05	0.000238	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—kidney cancer	6.86e-05	0.000237	CcSEcCtD
Ziprasidone—Dizziness—Vincristine—kidney cancer	6.85e-05	0.000236	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—kidney cancer	6.82e-05	0.000235	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—kidney cancer	6.82e-05	0.000235	CcSEcCtD
Ziprasidone—Confusional state—Capecitabine—kidney cancer	6.81e-05	0.000235	CcSEcCtD
Ziprasidone—Feeling abnormal—Paclitaxel—kidney cancer	6.78e-05	0.000234	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Paclitaxel—kidney cancer	6.73e-05	0.000232	CcSEcCtD
Ziprasidone—Diarrhoea—Gemcitabine—kidney cancer	6.72e-05	0.000232	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—kidney cancer	6.71e-05	0.000231	CcSEcCtD
Ziprasidone—Infection—Capecitabine—kidney cancer	6.71e-05	0.000231	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—kidney cancer	6.69e-05	0.000231	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—kidney cancer	6.65e-05	0.000229	CcSEcCtD
Ziprasidone—Shock—Capecitabine—kidney cancer	6.64e-05	0.000229	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—kidney cancer	6.63e-05	0.000229	CcSEcCtD
Ziprasidone—Nervous system disorder—Capecitabine—kidney cancer	6.62e-05	0.000228	CcSEcCtD
Ziprasidone—Thrombocytopenia—Capecitabine—kidney cancer	6.61e-05	0.000228	CcSEcCtD
Ziprasidone—Tachycardia—Capecitabine—kidney cancer	6.59e-05	0.000227	CcSEcCtD
Ziprasidone—Vomiting—Vincristine—kidney cancer	6.59e-05	0.000227	CcSEcCtD
Ziprasidone—Skin disorder—Capecitabine—kidney cancer	6.56e-05	0.000226	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—kidney cancer	6.54e-05	0.000226	CcSEcCtD
Ziprasidone—Urticaria—Paclitaxel—kidney cancer	6.54e-05	0.000225	CcSEcCtD
Ziprasidone—Rash—Vincristine—kidney cancer	6.53e-05	0.000225	CcSEcCtD
Ziprasidone—Hyperhidrosis—Capecitabine—kidney cancer	6.53e-05	0.000225	CcSEcCtD
Ziprasidone—Dermatitis—Vincristine—kidney cancer	6.53e-05	0.000225	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—kidney cancer	6.51e-05	0.000224	CcSEcCtD
Ziprasidone—Body temperature increased—Paclitaxel—kidney cancer	6.5e-05	0.000224	CcSEcCtD
Ziprasidone—Abdominal pain—Paclitaxel—kidney cancer	6.5e-05	0.000224	CcSEcCtD
Ziprasidone—Headache—Vincristine—kidney cancer	6.49e-05	0.000224	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—kidney cancer	6.44e-05	0.000222	CcSEcCtD
Ziprasidone—Anorexia—Capecitabine—kidney cancer	6.44e-05	0.000222	CcSEcCtD
Ziprasidone—Hypotension—Capecitabine—kidney cancer	6.31e-05	0.000218	CcSEcCtD
Ziprasidone—Vomiting—Gemcitabine—kidney cancer	6.25e-05	0.000216	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—kidney cancer	6.24e-05	0.000215	CcSEcCtD
Ziprasidone—Rash—Gemcitabine—kidney cancer	6.2e-05	0.000214	CcSEcCtD
Ziprasidone—Dermatitis—Gemcitabine—kidney cancer	6.19e-05	0.000214	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—kidney cancer	6.16e-05	0.000212	CcSEcCtD
Ziprasidone—Headache—Gemcitabine—kidney cancer	6.16e-05	0.000212	CcSEcCtD
Ziprasidone—Nausea—Vincristine—kidney cancer	6.15e-05	0.000212	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Capecitabine—kidney cancer	6.15e-05	0.000212	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—kidney cancer	6.14e-05	0.000212	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—kidney cancer	6.13e-05	0.000211	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—kidney cancer	6.13e-05	0.000211	CcSEcCtD
Ziprasidone—Insomnia—Capecitabine—kidney cancer	6.11e-05	0.000211	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—kidney cancer	6.1e-05	0.00021	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—kidney cancer	6.08e-05	0.00021	CcSEcCtD
Ziprasidone—Paraesthesia—Capecitabine—kidney cancer	6.06e-05	0.000209	CcSEcCtD
Ziprasidone—Hypersensitivity—Paclitaxel—kidney cancer	6.06e-05	0.000209	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—kidney cancer	6.05e-05	0.000209	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—kidney cancer	6.03e-05	0.000208	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—kidney cancer	6.02e-05	0.000208	CcSEcCtD
Ziprasidone—Dyspnoea—Capecitabine—kidney cancer	6.02e-05	0.000208	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—kidney cancer	6.01e-05	0.000207	CcSEcCtD
Ziprasidone—Dyspepsia—Capecitabine—kidney cancer	5.94e-05	0.000205	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—kidney cancer	5.9e-05	0.000204	CcSEcCtD
Ziprasidone—Asthenia—Paclitaxel—kidney cancer	5.9e-05	0.000204	CcSEcCtD
Ziprasidone—Decreased appetite—Capecitabine—kidney cancer	5.87e-05	0.000202	CcSEcCtD
Ziprasidone—Nausea—Gemcitabine—kidney cancer	5.84e-05	0.000201	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Capecitabine—kidney cancer	5.83e-05	0.000201	CcSEcCtD
Ziprasidone—Fatigue—Capecitabine—kidney cancer	5.82e-05	0.000201	CcSEcCtD
Ziprasidone—Constipation—Capecitabine—kidney cancer	5.77e-05	0.000199	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—kidney cancer	5.73e-05	0.000197	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—kidney cancer	5.71e-05	0.000197	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—kidney cancer	5.69e-05	0.000196	CcSEcCtD
Ziprasidone—Diarrhoea—Paclitaxel—kidney cancer	5.63e-05	0.000194	CcSEcCtD
Ziprasidone—Feeling abnormal—Capecitabine—kidney cancer	5.56e-05	0.000192	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—kidney cancer	5.56e-05	0.000192	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—kidney cancer	5.53e-05	0.000191	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Capecitabine—kidney cancer	5.52e-05	0.00019	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—kidney cancer	5.52e-05	0.00019	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—kidney cancer	5.5e-05	0.00019	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—kidney cancer	5.47e-05	0.000189	CcSEcCtD
Ziprasidone—Dizziness—Paclitaxel—kidney cancer	5.44e-05	0.000188	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—kidney cancer	5.41e-05	0.000187	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—kidney cancer	5.37e-05	0.000185	CcSEcCtD
Ziprasidone—Urticaria—Capecitabine—kidney cancer	5.36e-05	0.000185	CcSEcCtD
Ziprasidone—Abdominal pain—Capecitabine—kidney cancer	5.34e-05	0.000184	CcSEcCtD
Ziprasidone—Body temperature increased—Capecitabine—kidney cancer	5.34e-05	0.000184	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—kidney cancer	5.33e-05	0.000184	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—kidney cancer	5.33e-05	0.000184	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—kidney cancer	5.25e-05	0.000181	CcSEcCtD
Ziprasidone—Vomiting—Paclitaxel—kidney cancer	5.23e-05	0.00018	CcSEcCtD
Ziprasidone—Rash—Paclitaxel—kidney cancer	5.19e-05	0.000179	CcSEcCtD
Ziprasidone—Dermatitis—Paclitaxel—kidney cancer	5.18e-05	0.000179	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—kidney cancer	5.16e-05	0.000178	CcSEcCtD
Ziprasidone—Headache—Paclitaxel—kidney cancer	5.15e-05	0.000178	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—kidney cancer	5.13e-05	0.000177	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—kidney cancer	5.03e-05	0.000173	CcSEcCtD
Ziprasidone—Hypersensitivity—Capecitabine—kidney cancer	4.97e-05	0.000172	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—kidney cancer	4.93e-05	0.00017	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—kidney cancer	4.9e-05	0.000169	CcSEcCtD
Ziprasidone—Nausea—Paclitaxel—kidney cancer	4.89e-05	0.000169	CcSEcCtD
Ziprasidone—Asthenia—Capecitabine—kidney cancer	4.84e-05	0.000167	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—kidney cancer	4.79e-05	0.000165	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—kidney cancer	4.78e-05	0.000165	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—kidney cancer	4.77e-05	0.000165	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—kidney cancer	4.71e-05	0.000163	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—kidney cancer	4.69e-05	0.000162	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—kidney cancer	4.65e-05	0.000161	CcSEcCtD
Ziprasidone—Diarrhoea—Capecitabine—kidney cancer	4.62e-05	0.000159	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—kidney cancer	4.6e-05	0.000159	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—kidney cancer	4.54e-05	0.000157	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—kidney cancer	4.54e-05	0.000157	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—kidney cancer	4.54e-05	0.000157	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—kidney cancer	4.52e-05	0.000156	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.51e-05	0.000156	CcSEcCtD
Ziprasidone—Dizziness—Capecitabine—kidney cancer	4.46e-05	0.000154	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—kidney cancer	4.44e-05	0.000153	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—kidney cancer	4.39e-05	0.000151	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—kidney cancer	4.32e-05	0.000149	CcSEcCtD
Ziprasidone—Vomiting—Capecitabine—kidney cancer	4.29e-05	0.000148	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—kidney cancer	4.28e-05	0.000148	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—kidney cancer	4.27e-05	0.000147	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—kidney cancer	4.26e-05	0.000147	CcSEcCtD
Ziprasidone—Rash—Capecitabine—kidney cancer	4.26e-05	0.000147	CcSEcCtD
Ziprasidone—Dermatitis—Capecitabine—kidney cancer	4.25e-05	0.000147	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—kidney cancer	4.25e-05	0.000147	CcSEcCtD
Ziprasidone—Headache—Capecitabine—kidney cancer	4.23e-05	0.000146	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—kidney cancer	4.23e-05	0.000146	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—kidney cancer	4.21e-05	0.000145	CcSEcCtD
Ziprasidone—Clozapine—ABCB1—kidney cancer	4.16e-05	0.152	CrCbGaD
Ziprasidone—Anorexia—Doxorubicin—kidney cancer	4.15e-05	0.000143	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—kidney cancer	4.07e-05	0.00014	CcSEcCtD
Ziprasidone—Nausea—Capecitabine—kidney cancer	4.01e-05	0.000138	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—kidney cancer	3.97e-05	0.000137	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—kidney cancer	3.94e-05	0.000136	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—kidney cancer	3.91e-05	0.000135	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—kidney cancer	3.88e-05	0.000134	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—kidney cancer	3.87e-05	0.000133	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—kidney cancer	3.83e-05	0.000132	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—kidney cancer	3.78e-05	0.00013	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—kidney cancer	3.76e-05	0.00013	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—kidney cancer	3.75e-05	0.000129	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—kidney cancer	3.72e-05	0.000128	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—kidney cancer	3.59e-05	0.000124	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—kidney cancer	3.56e-05	0.000123	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—kidney cancer	3.46e-05	0.000119	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—kidney cancer	3.44e-05	0.000119	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—kidney cancer	3.44e-05	0.000119	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—kidney cancer	3.21e-05	0.000111	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—kidney cancer	3.12e-05	0.000108	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—kidney cancer	2.98e-05	0.000103	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—kidney cancer	2.88e-05	9.93e-05	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—kidney cancer	2.77e-05	9.54e-05	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—kidney cancer	2.74e-05	9.47e-05	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—kidney cancer	2.74e-05	9.46e-05	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—kidney cancer	2.73e-05	9.4e-05	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—kidney cancer	2.59e-05	8.92e-05	CcSEcCtD
Ziprasidone—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	3.43e-06	4.71e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KRAS—kidney cancer	3.43e-06	4.71e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—JUN—kidney cancer	3.43e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL2—kidney cancer	3.43e-06	4.7e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	3.42e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	3.42e-06	4.69e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTEN—kidney cancer	3.41e-06	4.68e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—RAF1—kidney cancer	3.41e-06	4.68e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—PIK3CA—kidney cancer	3.41e-06	4.68e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—RAF1—kidney cancer	3.41e-06	4.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	3.41e-06	4.67e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	3.4e-06	4.67e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—RELA—kidney cancer	3.4e-06	4.66e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—RAF1—kidney cancer	3.4e-06	4.66e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—RELA—kidney cancer	3.39e-06	4.65e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MTOR—kidney cancer	3.39e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—RAF1—kidney cancer	3.38e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MYC—kidney cancer	3.38e-06	4.64e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—RELA—kidney cancer	3.38e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ERBB2—kidney cancer	3.38e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—PIK3CA—kidney cancer	3.38e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL2—kidney cancer	3.37e-06	4.63e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ERBB2—kidney cancer	3.37e-06	4.62e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—RELA—kidney cancer	3.37e-06	4.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	3.37e-06	4.62e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KRAS—kidney cancer	3.36e-06	4.61e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ERBB2—kidney cancer	3.36e-06	4.61e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—RAF1—kidney cancer	3.35e-06	4.6e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ERBB2—kidney cancer	3.35e-06	4.59e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—RAF1—kidney cancer	3.34e-06	4.58e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCND1—kidney cancer	3.34e-06	4.58e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—RELA—kidney cancer	3.34e-06	4.58e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.33e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—JUN—kidney cancer	3.33e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PTEN—kidney cancer	3.33e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MTOR—kidney cancer	3.33e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—RELA—kidney cancer	3.33e-06	4.56e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MTOR—kidney cancer	3.33e-06	4.56e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PTEN—kidney cancer	3.32e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ERBB2—kidney cancer	3.32e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MTOR—kidney cancer	3.31e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MAPK3—kidney cancer	3.31e-06	4.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	3.31e-06	4.54e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MAPK1—kidney cancer	3.31e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	3.31e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KRAS—kidney cancer	3.31e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MTOR—kidney cancer	3.3e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—kidney cancer	3.29e-06	4.51e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCND1—kidney cancer	3.29e-06	4.51e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—JUN—kidney cancer	3.28e-06	4.5e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MTOR—kidney cancer	3.27e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MAPK3—kidney cancer	3.27e-06	4.48e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MTOR—kidney cancer	3.26e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KRAS—kidney cancer	3.26e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	3.26e-06	4.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTEN—kidney cancer	3.23e-06	4.42e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MYC—kidney cancer	3.22e-06	4.42e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CDKN1B—kidney cancer	3.18e-06	4.36e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MYC—kidney cancer	3.18e-06	4.36e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—PIK3CA—kidney cancer	3.18e-06	4.36e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTEN—kidney cancer	3.17e-06	4.35e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—PIK3CA—kidney cancer	3.17e-06	4.35e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	3.15e-06	4.32e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MAPK1—kidney cancer	3.15e-06	4.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTEN—kidney cancer	3.13e-06	4.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	3.13e-06	4.29e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	3.13e-06	4.29e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KRAS—kidney cancer	3.12e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CDKN1B—kidney cancer	3.12e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	3.12e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	3.11e-06	4.27e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2—kidney cancer	3.11e-06	4.27e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MAPK1—kidney cancer	3.11e-06	4.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RAF1—kidney cancer	3.11e-06	4.26e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CDKN1B—kidney cancer	3.1e-06	4.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RELA—kidney cancer	3.09e-06	4.24e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	3.09e-06	4.23e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—kidney cancer	3.07e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	3.07e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CDKN1B—kidney cancer	3.07e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—kidney cancer	3.07e-06	4.21e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	3.06e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2—kidney cancer	3.06e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2—kidney cancer	3.05e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—kidney cancer	3.05e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2—kidney cancer	3.04e-06	4.17e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—PIK3CA—kidney cancer	3.04e-06	4.17e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2—kidney cancer	3.03e-06	4.16e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCND1—kidney cancer	3.03e-06	4.16e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MTOR—kidney cancer	3.03e-06	4.16e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—JUN—kidney cancer	3.03e-06	4.15e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—kidney cancer	3.01e-06	4.13e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2—kidney cancer	3.01e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CTNNB1—kidney cancer	3e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—PIK3CA—kidney cancer	3e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2—kidney cancer	3e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—kidney cancer	3e-06	4.11e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—kidney cancer	2.99e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCND1—kidney cancer	2.98e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—JUN—kidney cancer	2.98e-06	4.08e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCND1—kidney cancer	2.98e-06	4.08e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KRAS—kidney cancer	2.98e-06	4.08e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—JUN—kidney cancer	2.97e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCND1—kidney cancer	2.97e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—JUN—kidney cancer	2.96e-06	4.06e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCND1—kidney cancer	2.96e-06	4.06e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	2.95e-06	4.05e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—kidney cancer	2.95e-06	4.05e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—JUN—kidney cancer	2.95e-06	4.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	2.95e-06	4.05e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CTNNB1—kidney cancer	2.95e-06	4.04e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	2.94e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—kidney cancer	2.94e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—kidney cancer	2.94e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—POMC—kidney cancer	2.94e-06	4.02e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCND1—kidney cancer	2.93e-06	4.02e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CTNNB1—kidney cancer	2.93e-06	4.02e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTEN—kidney cancer	2.93e-06	4.01e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—JUN—kidney cancer	2.92e-06	4.01e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCND1—kidney cancer	2.92e-06	4.01e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—JUN—kidney cancer	2.92e-06	4e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	2.91e-06	3.99e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CTNNB1—kidney cancer	2.9e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—kidney cancer	2.9e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	2.89e-06	3.97e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—kidney cancer	2.88e-06	3.95e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—kidney cancer	2.87e-06	3.94e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—kidney cancer	2.87e-06	3.94e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PIK3CA—kidney cancer	2.87e-06	3.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—kidney cancer	2.87e-06	3.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	2.87e-06	3.93e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—kidney cancer	2.86e-06	3.93e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—kidney cancer	2.86e-06	3.92e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK3—kidney cancer	2.85e-06	3.91e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	2.85e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK3—kidney cancer	2.83e-06	3.89e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—kidney cancer	2.83e-06	3.88e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—kidney cancer	2.82e-06	3.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	2.81e-06	3.85e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—kidney cancer	2.8e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ABCB1—kidney cancer	2.8e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—kidney cancer	2.78e-06	3.82e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—kidney cancer	2.78e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—kidney cancer	2.77e-06	3.8e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	2.76e-06	3.78e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—kidney cancer	2.76e-06	3.78e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.74e-06	3.76e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—kidney cancer	2.73e-06	3.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—kidney cancer	2.72e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTM1—kidney cancer	2.72e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—kidney cancer	2.71e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	2.71e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MAPK1—kidney cancer	2.71e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—JUN—kidney cancer	2.71e-06	3.71e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—kidney cancer	2.7e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MAPK1—kidney cancer	2.7e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	2.69e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—kidney cancer	2.68e-06	3.68e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—kidney cancer	2.65e-06	3.64e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—kidney cancer	2.65e-06	3.63e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—kidney cancer	2.64e-06	3.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—kidney cancer	2.64e-06	3.62e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	2.62e-06	3.6e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—kidney cancer	2.62e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—kidney cancer	2.61e-06	3.58e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—kidney cancer	2.6e-06	3.57e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—kidney cancer	2.6e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—kidney cancer	2.59e-06	3.55e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	2.58e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—kidney cancer	2.58e-06	3.54e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.57e-06	3.53e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—kidney cancer	2.56e-06	3.51e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—kidney cancer	2.55e-06	3.5e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	2.55e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—kidney cancer	2.55e-06	3.49e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK3—kidney cancer	2.5e-06	3.43e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—POMC—kidney cancer	2.49e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—kidney cancer	2.48e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK3—kidney cancer	2.46e-06	3.37e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK3—kidney cancer	2.46e-06	3.37e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK3—kidney cancer	2.45e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK3—kidney cancer	2.44e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—kidney cancer	2.44e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	2.44e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—kidney cancer	2.43e-06	3.34e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK3—kidney cancer	2.42e-06	3.31e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.41e-06	3.3e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—kidney cancer	2.41e-06	3.3e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—kidney cancer	2.39e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—kidney cancer	2.39e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—kidney cancer	2.38e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MAPK1—kidney cancer	2.38e-06	3.26e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—kidney cancer	2.37e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	2.37e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—kidney cancer	2.36e-06	3.23e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	2.35e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—kidney cancer	2.35e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.34e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MAPK1—kidney cancer	2.34e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—kidney cancer	2.34e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	2.34e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MAPK1—kidney cancer	2.34e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MAPK1—kidney cancer	2.33e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MAPK1—kidney cancer	2.32e-06	3.18e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MAPK1—kidney cancer	2.3e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.29e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	2.28e-06	3.12e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—kidney cancer	2.27e-06	3.12e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—kidney cancer	2.26e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—kidney cancer	2.25e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	2.24e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	2.24e-06	3.07e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—kidney cancer	2.21e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—kidney cancer	2.21e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—kidney cancer	2.21e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—kidney cancer	2.2e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—kidney cancer	2.2e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—kidney cancer	2.19e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—kidney cancer	2.18e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—kidney cancer	2.17e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—kidney cancer	2.17e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—kidney cancer	2.17e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	2.13e-06	2.92e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—kidney cancer	2.06e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—kidney cancer	2.04e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	2.03e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—kidney cancer	2.03e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—kidney cancer	2.03e-06	2.78e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.02e-06	2.77e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—kidney cancer	2.01e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—kidney cancer	2.01e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—kidney cancer	2e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—kidney cancer	1.99e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	1.99e-06	2.73e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—kidney cancer	1.98e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—kidney cancer	1.97e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—kidney cancer	1.96e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—kidney cancer	1.95e-06	2.68e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—kidney cancer	1.95e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—kidney cancer	1.93e-06	2.65e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—kidney cancer	1.92e-06	2.64e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—POMC—kidney cancer	1.92e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	1.85e-06	2.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—kidney cancer	1.79e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—kidney cancer	1.73e-06	2.37e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—kidney cancer	1.53e-06	2.1e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.44e-06	1.98e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—kidney cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.22e-06	1.67e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—kidney cancer	9.42e-07	1.29e-05	CbGpPWpGaD
